Acasti Pharma, Inc.
ACST
ACST: Acasti Pharma Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. Its novel drug delivery technologies have the potential to improve the performance of marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery all of which could help to increase treatment compliance and improve patient outcomes.
moreShow ACST Financials
Recent trades of ACST by members of U.S. Congress
| Politician | Type | Traded |
|---|---|---|
| Mark Dr Green House / R | Purchase $1,001 - $15,000 | Mar. 16, 2021 |
Recently reported changes by institutional investors
Quarterly net insider trading by ACST's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Apparatus for metering and dispensing viscous substance May. 10, 2022
-
Patent Title: Concentrated therapeutic phospholipid compositions Nov. 20, 2018
-
Patent Title: Concentrated therapeutic phospholipid compositions Oct. 25, 2016
-
Patent Title: Concentrated therapeutic phospholipid compositions Nov. 19, 2013
Federal grants, loans, and purchases
Followers on ACST's company Twitter account
Number of mentions of ACST in WallStreetBets Daily Discussion
Recent insights relating to ACST
Recent picks made for ACST stock on CNBC
ETFs with the largest estimated holdings in ACST
Flights by private jets registered to ACST